Endothelial progenitor cells are associated with response to chemotherapy in human non-small-cell lung cancer

Purpose Bone marrow-derived endothelial progenitor cells (EPCs) play an important role in angiogenesis and tumor growth. However, the clinical relevance of EPCs in non-small-cell lung cancer (NSCLC) remains unclear. Recently, some reports suggested that EPCs correlate with clinical behavior of cance...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cancer research and clinical oncology 2011-12, Vol.137 (12), p.1849-1857
Main Authors: Morita, Ryo, Sato, Kazuhiro, Nakano, Mariko, Miura, Hajime, Odaka, Hidesato, Nobori, Kiyoshi, Kosaka, Toshimitsu, Sano, Masaaki, Watanabe, Hiroyuki, Shioya, Takanobu, Ito, Hiroshi
Format: Article
Language:English
Subjects:
AC133 Antigen
Aged
Aged, 80 and over
Antigens, CD - analysis
Antineoplastic agents
Biological and medical sciences
Biomarkers
Cancer Research
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - mortality
Chemotherapy
Disease-Free Survival
Endothelial Cells - cytology
Female
Glycoproteins - analysis
Hematology
Humans
Interleukin-8 - blood
Internal Medicine
Lung cancer
Lung Neoplasms - drug therapy
Lung Neoplasms - mortality
Male
Medical prognosis
Medical sciences
Medicine
Medicine & Public Health
Middle Aged
Oncology
Original Paper
Peptides - analysis
Pharmacology. Drug treatments
Pneumology
Stem Cells - physiology
Tumors of the respiratory system and mediastinum
Vascular Endothelial Growth Factor A - blood
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Bone marrow-derived endothelial progenitor cells (EPCs) play an important role in angiogenesis and tumor growth. However, the clinical relevance of EPCs in non-small-cell lung cancer (NSCLC) remains unclear. Recently, some reports suggested that EPCs correlate with clinical behavior of cancer patients. We assessed the hypothesis that EPCs correlate with efficient of therapy, prognosis, and clinicopathological factors, and EPCs may offer a possible biomarker for treatment outcome in NSCLC. Methods EPCs labeled with CD34, CD133, and vascular endothelial growth factor receptor-2 (VEGFR-2) antibodies were counted by flow cytometry in the peripheral blood of 31 NSCLC patients. We categorized two groups of NSCLC patients according to circulating EPC numbers. We examined age, pathological stage, histological type, Fluoro- d -glucose Positron emission tomography (FDG-PET ) , response to therapy, progression-free survival, and tumor size of NSCLC patients and investigated whether these factors correlate with EPC counts. Results Circulating EPC numbers before antitumor therapy were increased in NSCLC patients compared with healthy controls ( P  
ISSN:0171-5216
1432-1335
DOI:10.1007/s00432-011-1043-8